AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

FBI Approves Verogen’s Next-Gen Forensic DNA Technology for National DNA Index System

May 2, 2019

SAN DIEGO--(BUSINESS WIRE)--May 2, 2019--Verogen Inc., the world’s first DNA sequencing company dedicated to forensic science, announced today that the United States Federal Bureau of Investigation has approved the company’s next-gen forensic DNA technology for use by forensic laboratories generating DNA profiles for upload to the National DNA Index System (NDIS). The FBI manages NDIS to enable comparison of eligible DNA profiles contributed by participating federal, state, and municipal forensic laboratories.

Verogen’s MiSeq FGx ® Forensic Genomics System is the first NDIS approved solution for genomic DNA analysis that harnesses “Next Generation Sequencing” (NGS) technology to dramatically increase profiling efficiency and data recovery from biological evidence.

“This is an important advancement,” said Dr. Jenifer Smith, Director of the Washington, D.C., Department of Forensic Sciences. Dr. Smith’s laboratory was part of the consortium of forensic U.S. laboratories that submitted internal validation results to the FBI as part of the NDIS approval process.

“NGS enables us to efficiently generate more comprehensive and useful data. This means we will be able to aid more investigations and close more cases,” Dr. Smith said.

The MiSeq FGx ® Forensic Genomics System is a sample-to-answer workflow including the ForenSeq ™ DNA Signature Prep kit, MiSeq FGx ® sequencing instrument platform, and ForenSeq ™ Universal Analysis Software. The system allows forensic scientists to analyze up to 231 genomic DNA markers simultaneously—supplying significantly more actionable data than commonly analyzed using older methods. The Verogen system can develop more detailed profiles from degraded, mixed, and limited biological evidence samples, addressing a wider range of forensic questions in a single test.

With NDIS approval granted, U.S. forensic laboratories can now access a much larger pool of federal funding administered by the National Institute of Justice to adopt and implement this powerful crime fighting tool.

“Obtaining NDIS approval is an enormous step forward for the forensic genomics community, and for mainstream adoption of this technology,” said Brett Williams, Verogen CEO. “Verogen is proud to advance the transition of NGS technology from a visionary method to a fully validated, NDIS-approved tool for forensic science.”

The MiSeq FGx ® Forensic Genomics System is available worldwide. It has been approved for use in the national DNA databases of France and the Netherlands—and now the United States.

About Verogen, Inc.

Verogen is committed to public safety and justice for all. Headquartered in the San Diego area, we serve those who pursue the truth using genetic tools. Powered by gold standard Illumina sequencing technology and working in partnership with forensic laboratories, Verogen is advancing science to unlock the true potential of forensic genomics. For more information, visit  www.verogen.com.

https://twitter.com/VerogenBio
https://www.facebook.com/VerogenBio/
https://www.linkedin.com/company/verogen

For Research, Forensic and Paternity Use Only. Not for use in diagnostic procedures.

© 2019 Verogen, Inc. All rights reserved.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190502005888/en/

CONTACT: Jonathan Tabak – Director, Market Development

jtabak@verogen.com

504-913-6845

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CALIFORNIA IRELAND

INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH BIOTECHNOLOGY GENETICS DEFENSE OTHER DEFENSE RESEARCH OTHER SCIENCE SCIENCE

SOURCE: Verogen, Inc.

Copyright Business Wire 2019.

PUB: 05/02/2019 04:00 PM/DISC: 05/02/2019 04:00 PM

http://www.businesswire.com/news/home/20190502005888/en